Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-636-9 | CAS number: 108-99-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
A chronic bioassay demonstrated lung and liver tumors, primarily in mice.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 9 Nov 2004 - 10 Nov 2006
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline carcinogencity study by the U.S. National Toxicology Program
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: Specifications for the Conduct of Studies to Evaluate the Toxic and Carcinogenic Potential of Chemical, Biological, and Physical Agents in Laboratory Animals for the National Toxicology Program (NTP) October 2006
- Principles of method if other than guideline:
- The guideline "Specifications for the Conduct of Studies to Evaluate the Toxic and Carcinogenic Potential of Chemical, Biological, and Physical Agents in Laboratory Animals for the National Toxicology Program (NTP), October 2006" is similar to the OECD Combined Toxicity/Carcinogenicity Guideline 453.
- GLP compliance:
- yes
- Species:
- mouse
- Strain:
- B6C3F1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms, Germantown, NY, USA
- Age at study initiation: 5-6 weeks
- Fasting period before study: 11-12 days
- Housing: Cages and racks were rotated every two weeks during the study. See-Through Systems polycarbonate, solid bottom (Lab Products, Inc., Rochelle Park, NJ), changed twice per week. Heat-treated hardwood chips (P.J. Murphy Forest Products, Montville, NJ), changed weekly (mice).
- Diet (e.g. ad libitum): Irradiated NTP-2000 wafer feed (Zeigler Brothers, Inc., Gardners, PA), available ad libitum
- Water (e.g. ad libitum): Tap water via glass water bottles with stainless steel sipper tubes, available ad libitum, changed twice per week.
- Acclimation period: up to 12 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3
- Humidity (%): 50% +/-15%
- Air changes (per hr): 10/hour
- Photoperiod (hrs dark / hrs light): 12 /12
IN-LIFE DATES: From: 9 Nov (males) or 8 Nov (females) 2004. To: 10 Nov (males) or 8 Nov (females) 2006 - Route of administration:
- oral: drinking water
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Dosing solutions were prepared every 4 weeks for the 2-year studies by mixing the test material with tap water. The pH was adjusted if necessary with acetic acid to bring it to 6-7.5 pH units. Stability studies of 10 µl/ml formulations were performed periodically by HPLC with ultraviolet light detection and found to be stable (± 10%) under the animal room conditions. They were made and stored in sealed polyethylene bottles. The water was administered to animals in glass bottles with stainless steel sipper tubes and Teflon® seals. Analytical data indicate that little or no volatization occurred under these conditions.
- Duration of treatment / exposure:
- 105 weeks
- Frequency of treatment:
- daily, 7 days per week
- Remarks:
- Doses / Concentrations:
312.5 mg/L
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
625 mg/L
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
1250 mg/L
Basis:
actual ingested - No. of animals per sex per dose:
- 50 per sex per dose group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Male mice were housed 1 per cage, females were housed 5 per cage
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Clinical findings were recorded weekly
BODY WEIGHT: Yes
- Time schedule for examinations: Body weights were recorded at the start of the study, weekly for the first 3 months,
and then once every 2 weeks until study termination.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: Water consumption was measured weekly by cage for the first 3 months and every 4 weeks thereafter. Female mice were housed 5 per cage, and male mice housed 1 per cage.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- Sacrificed by CO2 asphyxiation.
HISTOPATHOLOGY: Complete histopathology was performed on all mice. In addition to gross lesions and tissue masses, the following tissues were observed microscopically. The following tissues were examined: adrenal gland, bone (with marrow), brain, clitoral gland, esophagus, eyes, gallbladder, Harderian gland, heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, liver, lung, lymph nodes (mandibular and mesenteric), mammary gland, nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, skin, salivary gland, spleen, stomach (forestomach and glandular), testis (with epididymis and seminal vesicle), thymus, thyroid gland, tongue, trachea, urinary bladder and uterus. - Statistics:
- The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958), or Cox’s method (1972) for testing two groups for equality. Tarone’s life table test (1975) was used to identify dose-related trends. All reported P values for the survival analysis were two sided.
Survival-adjusted neoplasm rates for each group and each site-specific neoplasm are given. The survival-adjusted Poly-k test (Bailer and Portier, 1988; Portier and Bailer, 1989; Piegorsch and Bailer, 1997) was used to assess neoplasm and nonneoplastic lesion prevalence, with k= 3 as recommended by Bailer and Portier, 1988. Tests of significance included pairwise comparisons of each dosed group with controls and a test for an overall dose-related trend. Continuity-corrected Poly-3 tests were used in the analysis of lesion incidence, and reported P values are 1-sided. The significant of lower incidences or decreasing trends in lesions is represented as 1-P with a post-script “N”.
For continuous variables, organ and body weight data were analyzed with the parametric multiple comparison procedures of Dunnett (1955) and Williams (1971, 1972). For skewed distribution values (clinical chemistry, etc.), nonparametric multiple comparison methods were used to assess the significance of the dose-related trends.
Historical control values for a given route of administration were used to assist in interpretation of control and experimental values. The relevant historical control database includes studies undertaken after 2000 when a modified diet was adopted. - Clinical signs:
- no effects observed
- Description (incidence and severity):
- Survival rates were comparable for animals in test groups compared to controls. No clinical findings related to 3-methylpyridine were observed.
- Mortality:
- no mortality observed
- Description (incidence):
- Survival rates were comparable for animals in test groups compared to controls. No clinical findings related to 3-methylpyridine were observed.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Mean body weights of the high dose group were 10% less than controls in males and females
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- Water consumption by males (mid and high doses) and females (high dose) was significantly decreased compared to that by controls.
- Ophthalmological findings:
- not examined
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Liver and lung tumours and changes in oral cavity epithelial structure were noted.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Abnormalities epithelium were noted in the alveolus and in nasal olfactory tissue.
- Histopathological findings: neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Liver and lung adenomas, liver carcinonomas and hepatoblastomas were documented.
- Details on results:
- Effect observed is an increased incidence of hepatocellular carcinoma/hepatoblastoma and combined alveolar/bronchiolar adenomas or carcinomas in females. The dose-response trend for alveolar/bronchiolar adenoma in females was statistically significant. However, alveolar/bronchiolar carcinomas in females were not significantly increased. When the incidences of alveolar/bronchiolar adenoma or carcinoma (combined) were compared with control incidences in females, statistical significance was achieved for the dose trend and at the high dose of 1250 mg/L. For alveolar/bronchiolar adenoma in females, the tumour incidences are: 5/50 in 0 mg/L, 6/50 in 312.5 mg/L, 4/49 in 625 mg/L and 11/50 of 1250 mg/L (significant dose trend). For alveolar/bronchiolar adenoma or carcinoma (combined) in females, the tumour incidences are: 11/50 in 0 mg/L, 13/50 in 312.5 mg/L, 13/49 in 625 mg/L and 21/50 of 1250 mg/L (significant at the high dose, p < 0.05). The incidence of alveolar/bronchiolar adenoma was significantly increased in mid dose males. For alveolar/bronchiolar adenoma in males, the tumour incidences are: 6/50 in 0 mg/L, 11/50 in 312.5 mg/L, 16/50 in 625 mg/L and 8/50 of 1250 mg/L.
Nasal olfactory epithelial metaplasia and lung alveolar epithelial hyperplasia were significantly increased at the high dose of 1250 mg/L in both males and females (p < 0.05).
In female mice, liver tumours were also observed. For hepatocellular adenoma in females, the tumour incidences are: 38/50 in 0 mg/L, 46/50 in 312.5 mg/L, 46/50 in 625 mg/L and 39/50 of 1250 mg/L (significant at low and mid doses). Hepatocellular carcinomas were significantly increased in all exposed groups of females; the tumour incidences are: 11/49 in 0 mg/L, 20/50 in 312.5 mg/L, 26/50 in 625 mg/L and 23/50 of 1250 mg/L (significant at all doses with a significant dose trend). Hepatoblastomas were increased at all doses in females, but only the dose trend was statistically significant. For hepatocellular carcinoma or hepatoblastoma (combined) in females, the tumour incidences are: 12/49 in 0 mg/L, 21/50 in 312.5 mg/L, 28/50 in 625 mg/L and 24/50 of 1250 mg/L. These tumours were not increased in males.
The conclusions of the draft report are that, under the conditions of the 2-year study:
a) There was equivocal evidence of carcinogenic activity in male mice
b) There was clear evidence of carcinogenic activity in female B6C3F1 mice (increased incidence of alveolar/bronchiolar adenoma or adenoma/carcinoma (combined), p<0.05, and hepatocellular adenoma and carcinoma or hepatoblastoma (combined), p < 0.05). The conclusion meets the NTP criteria for “clear evidence” based on a dose-related increase in malignant neoplasms or an increase of a combination of benign and malignant neoplasms.
The finding of lung tumours after oral administration gives rise to questions of whether inhalation exposure of 3-methylpyridine has occurred. Lung and liver cancer incidence in mice are not highly relevant to human risk assessment. - Relevance of carcinogenic effects / potential:
- The finding of lung tumours after oral administration gives rise to questions of whether inhalation exposure of 3-methylpyridine has occurred. Lung cancer incidence in mice, which have a high background incidence, is not highly relevant to human risk assessment. Hepatic carcinoma and hepatoblastoma are not highly relevant to human risk assessment.
- Dose descriptor:
- NOAEL
- Effect level:
- < 18 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Equivalent to 26 mg/kg bw/d (males)
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified. Effect type:carcinogenicity (migrated information)
- Conclusions:
- A two-year cancer bioassay in B6C3F1 mice was undertaken with 3-methylpyridine in drinking water. The conclusions of a draft report are available, with findings of “equivocal evidence” of carcinogenic activity in male mice based on increased incidences of alveolar/bronchiolar adenoma and alveolar/bronchiolar adenoma or carcinoma (combined). There was “clear evidence” of carcinogenic activity in female mice based on increased incidences of alveolar/bronchiolar adenoma or carcinoma (combined) in the lung and hepatocellular carcinoma and hepatoblastoma (liver). The NOAEL is less than 312.5 mg/L, equivalent to 26 mg/kg bw/d in males and 18 mg/kg bw/day in females.
Reference
Table 1: Nonneoplastic Pathology in the Mouth, Nose and Lung in Rats or Mice in the 2-year Bioassay
Observation |
Species, sex |
Incidence and Dose |
Statistical Significance |
Comment |
Squamous cell papillomas and carcinomas, oral mucosa or tongue |
Rat, male and female |
1/50 in 312.5 and 1/50 in 625 mg/L |
NS |
occurred in less than 5% of any group, so not reported in detail. |
Nasal olfactory epithelial metaplasia |
Rats, females Mice, males and females |
Female Rats: 0/50 in 0, 3/50 in 156.25, 1/50 in 312.5 and 1/50 of 625 mg/L . Male mice: 8/50 in 0, 12/50 in 312.5, 30/50 in 625, and 41/50 in 1250 mg/L. Female mice: 2/49 in 0, 2/44 in 312.5, 7/49 in 625, 14/47 in 1250 mg/L |
NS
S at mid and high dose; p < 0.01
S at high dose; p < 0.01 |
|
Nasal olfactory epithelial atrophy |
Mice, males and females |
Male mice: 3/50 in 0, 4/50 in 312.5, 8/50 in 625, and 7/50 in 1250 mg/L. Female mice: 1/49 in 0, 2/44 in 312.5, 2/49 in 625, 7/47 in 1250 mg/L |
NS
S at high dose; p < 0.01 |
|
Lung alveolar epithelial hyperplasia |
Mice, males and females |
Male mice: 4/50 in 0, 6/50 in 312.5, 6/49 in 625, and 7/50 in 1250 mg/L. Female mice: 2/50 in 0, 4/50 in 312.5, 3/49 in 625, 8/50 in 1250 mg/L |
NS
S at high dose; p < 0.01 |
Females in 625 mg/L group also had 3 bronchiolar hyperplasias, not included. |
S: Statistically significant, p < 0.05
NS: Not statistically significant
Table 2: Incidence of Alveolar/Bronchiolar Tumors (Lung) and Liver in Rats and Mice Exposed to 3 -Methylpyridine
Observation |
Species, sex |
Incidence and Dose |
Statistical Significance |
Comment |
Alveolar/bronchiolar adenoma, carcinomas or combined |
Rat, male |
No difference from controls |
NS |
|
Alveolar/bronchiolar adenoma
Alveolar/bronchiolar Carcinoma
Alveolar/bronchiolar adenoma or carcinoma (combined) |
Rats, females
|
0/50 in 0, 3/50 in 156.25, 2/50 in 312.5 and 5/50 of 625 mg/L .
No difference from controls
0.50 in 0, 4/50 in 156.25, 2/50 in 312.5, and 5/50 in 625 mg/L |
S, p < 0.05
NS
S, p < 0.05
|
|
Alveolar/bronchiolar adenoma
Alveolar/bronchiolar Carcinoma
Carcinomas or combined |
Mice, males |
6/50 in 0, 11/50 in 312.5, 16/50 in 625, and 8/50 in 1250 mg/L.
No difference from controls
No difference from controls |
S at mid dose; p < 0.05
NS
NS |
|
Alveolar/bronchiolar adenoma
Alveolar/bronchiolar Carcinoma
Alveolar/bronchiolar adenoma or carcinoma (combined) |
Mice, females |
5/50 in 0, 6/50 in 312.5, 4/49 in 625, 11/50 in 1250 mg/L
No difference from controls
11/50 in 0, 13/50 in 312.5, 13/49 in 625, 21/50 in 1250 mg/L
|
S dose trend, p < 0.05
NS
S at high dose; p < 0.05 |
|
Hepatocellular adenoma
Hepatocellular carcinoma
Hepatocellular carcinoma or hepatoblastoma
Hepatocellular adenoma or carcinoma (combined)
|
Mice, females |
38/49 in 0, 46/50 in 312.5, 46/50 in 625, 39/50 in 1250 mg/L
11/49 in 0, 20/50 in 312.5, 26/50 in 625, 23/50 in 1250 mg/L
12/49 in 0, 21/50 in 312.5, 28/50 in 625, 24/50 in 1250 mg/L
No data provided |
S at low and mid dose, p < 0.05
S, all doses and dose trend, p < 0.05
S, all doses and dose trend, p < 0.05
|
|
S: Statistically significant, p < 0.05
NS: Not statistically significant
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 18 mg/kg bw/day
- Study duration:
- chronic
- Species:
- mouse
- Quality of whole database:
- adequate
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
A bioassay of 3 -methylpyridine in rats and mice showed lung and liver tumours primarily in mice, which have low relevance for cancer risk in humans. Methodologic issues with the study design (dehydration, potential for inhalation exposure) further complicate interpretation of results. A bioassay of pyridine resulted in some tumour development in rats and mice, but IARC determined that pyridine was not able to be classified as a human carcinogen.
There is insufficient evidence to classify pyridine and methylpyridine derivatives as carcinogens.
Additional information
A two-year cancer bioassay in rats and mice was undertaken with 3-methylpyridine in drinking water. The conclusions of a draft report are available, with findings of “clear evidence” of carcinogenic activity in female mice based on increased incidences of alveolar/bronchiolar adenoma or carcinoma (combined) in the lung and hepatocellular carcinoma and hepatoblastoma (liver). The NOAEL is the low dose of 312.5 mg/L, equivalent to 26 mg/kg bw/d in males and 18 mg/kg bw/day in females. There was “equivocal evidence” of carcinogenic activity in male mice based on increased incidences of lung adenoma and/or carcinoma (combined). There was “some evidence” of carcinogenic activity based on lung tumours in female rats at a rate slightly above the historical control levels, with a statistically significant trend test. There is incomplete understanding at this time of the carcinogenic potential of 3 -methylpyridine.
Carcinogencity was also examined in a chronic bioassay with pyridine (a category member with 2 -,3- and 4 -methylpyridine)
in the drinking water of F344 and Wistar rats, and B6C3F1 mice. Because of the development of alpha-2-microglobulinemia in the kidney, a second strain of rat, the Wistar, was used in a second bioassay. Tumors were observed in each strain of rat and mouse, but none were consistent over the 3 species. The NTP concluded that there was some evidence of carcinogenic activity of pyridine in F344 and Wistar rats, and in C3H6F1 mice. The International Agency for Cancer Research (IARC) reviewed this data and epidemiologic evidence and concluded that pyridine was not able to be classified as a human carcinogen.Justification for selection of carcinogenicity via oral route endpoint:
experimental result according to a guideline protocol
Carcinogenicity: via oral route (target organ): respiratory: lung
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.